NCT04723602 - Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

December 14, 2021

Study Completion Date

December 14, 2021

Conditions

Ebola Virus DiseaseMarburg Virus Disease

Interventions

BIOLOGICAL

cAd3-Marburg

A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10\^11 Particle Units (PU) vaccine.

BIOLOGICAL

cAd3-EBO-S

A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10\^11 Particle Units (PU) vaccine.

Trial Locations (1)

73104

Oklahoma Blood Institute (OBI), Oklahoma City